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 Mucosal vaccines, which are administered by oral or intranasal route, are 
more convenient than the usual parenteral vaccines due to their ease of administration 
and low cost. Both are priorities for developing countries plagued by infectious 
diseases when considering vaccination for public health policy. Moreover, mucosal 
vaccines are able to elicit serum-IgG and mucosal-IgA antibodies to neutralize toxins 
and viruses and induce cytotoxic T lymphocytes (CTL) activities .  
 In this context, we have embarked on the study of the use of Lactococcus 
lactis as a possible vaccine vector targeting dengue virus. This is a further study from 
previous work by Lin, W. (2006) who constructed a recombinant L. lactis strain 
producing in its cytoplasm the E domain III (EDIII) antigen from DEN2 virus, 
Singapore strain. L. lactis is a noninvasive, nonpathogenic, gram-positive bacterium 
which has a long history of widespread use in the food industry for the production of 
fermented milk products, thus it has a generally-regarded as safe (GRAS) status. Its 
GRAS status coupled to its inability to colonize the digestive and the respiratory 
tracts of both humans and mice, except gnotobiotic mice, make L. lactis a safe and 
attractive vaccine delivery vehicle for human use.  
This study aims to study the immunization efficacy, via measuring the 
systemic anti-EDIII antibody response generated in two different mouse strains, 
BALB/c and C57BL/6, after nasal or oral administration of the EDIII-producing L. 
lactis strain (LLWE-EDIII). The systemic specific anti-EDIII IgG responses were 
compared. Our data indicate that EDIII-producing L. lactis bacteria are able to trigger 
 vii
a strong and sustained antibody response against EDIII antigen in mice. Of the two 
strains and two routes of inoculation, it was observed that C57BL/6 mice inoculated 
via the nasal route were found to be the best responders. With the preliminary results 
of plaque reduction neutralization test (PRNT), the higher ELISA readings of anti-
EDIII IgG might not necessary translates to higher neutralizing ability against a 
homotypic dengue virus with 3 amino acid mutation in the region targeted. However, 
more PRNT needs to be done to validate this observation or otherwise. But the ability 
of the sera raised in mice inoculated with LLWE-EDIII to neutralize dengue virus 
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Chapter 1: Introduction 
 
Dengue virus is the causative agent for dengue fever, dengue haemorrhagic 
fever and dengue shock syndrome. Dengue infection is considered to be one of the 
most important arthropod-borne disease causing up to 25 000 deaths annually. The 
disease is endemic in subtropical and tropical countries in most of which proper care 
of the patients and proper vector control are lacking (Gubler, 2002, Burke et al., 
2001). Thus, the need for a vaccine that is cheap and easy to administer is urgent.  
 
This project aims as a proof-of-principle for Lactococcus lactis to be used as 
an effective dengue vaccine delivery vehicle through the oral or nasal route. L. lactis 
is a lactic bacterium whose GRAS (Generally Recognized As Safe) status represents 
an important advantage for its potential use as a live vehicle in humans. Moreover the 
use of lactic bacteria for vaccine delivery through the oral or nasal routes represents a 
very attractive means for vaccination in poor countries that can not afford parenteral 
injections. L. lactis has been previously shown to efficiently express heterologous 
proteins from various origins, and to trigger specific immune responses against the 
vaccine candidate (Steidler et al., 2000; Riberio et al., 2002; Xin et al., 2003 et al.,; 
Bermudez-Humaran et al., 2004; Pei et al., 2005; Perez et al., 2005; Zhang et al., 
2005). 
 
The dengue antigen E domain III has been selected for this project which had 
been shown to elicit protection in various vaccine delivery systems (Simmons et al, 
1998; Zhang et al., 1988; Bray et al., 1989; Lai et al., 1990). This antigen has been 




cloned and expressed into the cytoplasm of L. lactis and the recombinant strain has 
been administered to BALB/c and C57BL/6 mice via the nasal or the oral route. The 
colonization efficacy and the specific systemic antibody responses have then been 
analysed. 
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Chapter 2: SURVEY OF LITERATURE 
 
2.1  Dengue virus 
 
2.1.1  Classification 
 
Dengue virus (DEN) is a member of the genus flavivirius of the Flaviviridae 
family. Flaviviruses are separated into groups by serology and genome sequence 
relatedness (Calisher et al., 1989; Blok et al., 1992). Other major viruses in this genus 
include Japanese encephalitis virus (JEV), tick-borne encephalitis virus (TBEV), 
yellow fever virus (YFV) and West Nile virus (WNV). They are usually arthropod-
borne and are transmitted via infected tick or mosquito vectors. These viruses are of 
major global concern as they cause significant morbidity and mortality worldwide 
(Monath and Heinz, 1996). 
 
2.1.2 Structure of virions 
 Flaviviruses consist of spherical enveloped virions (diameter 40-60 nm) with 
host-derived lipid bilayer. The lipid envelope consists of 180 copies of 2 viral-derived 
type I membrane proteins, E (envelope) and M (membrane-like) (Kuhn et al., 2002). 
Dengue virus contains 7nm ring-shaped structures on the surface of its virus particles 
unlike most flaviviruses which do not contain regular surface projections (Smith et 
al.,1970). The viral RNA genome is associated with several copies of the basic capsid 
(C) protein (Chambers et al., 1990a) resulting in an electron-dense structure of 
approximately 30nm in diameter. 
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2.1.3 Organization of the dengue genome and translational process 
The genome of flaviviruses is a positive single-stranded RNA of approximately 
11kb (Chambers et al., 1990a). Its 5' terminus has a type 1 cap (m7GpppAmp) 
followed by the conserved dinucleotide sequence AG and its 3’ terminus consists of 
the conserved dinucleotide CU. The flaviviral RNA genome contains a large open 
reading frame of over 10,000 nucleotides encoding a single polyprotein precursor 
flanked by 5' and 3' untranslated regions. These regions contain conserved RNA 
elements had distinct conserved sequences are also found near the 5' and 3' terminus 
of mosquito-borne flaviviruses (Chambers et al., 1990a).  
The polyprotein precursor is co-translationally and post-translationally processed 
by host proteases (such as furin) and viral serine protease (such as NS2B-3 protease) 
to produce ten mature viral proteins: pre-M (prM)/ membrane (M)- Envelope (E)- 
NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3 (Chambers et al., 1990a). prM, M and E 
proteins constitute the structural proteins of the virus. Amongst these ten viral 
proteins, prM, E and NS1 are considered to elicit protective immunity as passive 
transfer of antibodies against each of these proteins had protected lethally challenged 
mice (Kaufman et al., 1987, Henchal et al., 1988, Kaufman et al.,1989,). 
 
2.1.4 Proteins encoded by the viral RNA 
2.1.4.1 Pre-M (prM) and Envelope (E) proteins 
The prM and E proteins have been shown to be involved in various aspects of 
the viral infection including pathogenicity (Leitmeyer et al., 1999), viral attenuation 
(Blok et al., 1992; Pryor et al., 2001), cell fusion properties (Lee et al., 1997), 
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neurovirulence (Sanchez and Ruiz, 1996) and virus-induced cell apoptosis (Duarte 
dos Santos et al., 2000).  
The flaviviral envelope contains two structural glycoproteins, namely 
envelope E (MW 53-54 kDa) and membrane-like M (MW 8 kDa). However, the 
dengue virus envelope contains a mixture of pre-M (prM, MW 26 kDa) and M 
proteins with a predominance of prM proteins (Rice, 1996; Wang et al., 1999). Virion 
assembly occurs in association with rough ER membranes where the prM and E 
proteins associate with each other to form a stable heterodimer (Wengler and 
Wengler, 1989, Allison et al., 1995b). This heterodimer is incorporated into immature 
virions during budding from the lumen (Mackenzie and Westaway, 2001). This 
association may be vital for the maintenance of E protein in a stable, fusion-inactive 
conformation before viral release (Konishi and Mason, 1993). It protects immature 
virions against inactivation during transport in acidic vesicles by stabilization of pH-
sensitive epitopes on the E protein (Guirakhoo et al., 1992; Heinz et al., 1994; Allison 
et al., 1995a). The immature virions are transported via the secretion pathway and, 
shortly before or coincident with their release, are converted to mature virions upon 
cleavage of prM protein to M proteins by cellular furin (Stadler et al., 1997).  
 The flaviviral E protein is the major envelope protein of the virion (Rice, 
1996) and is mostly glycosylated (Winkler et al., 1987; Chambers et al., 1990a). This 
protein is involved in receptor binding (Anderson et al.., 1992; Chen et al., 1996; 
Wang et al., 1999), membrane fusion (Schalich et al., 1996; Rice,1996), virion 
assembly (Stiasny et al., 2002) and is the primary target for neutralizing antibodies 
(Heinz, 1996). 
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The X-ray crystallographic structure of the E protein from TBEV and dengue-
2 virus has been resolved (Rey et al., 1995, Modis et al., 2003). The ectodomain of 
the protein folds into three distinct domains (I-III). The Domain I is the central 
structure in which the other two domains flank with on either side. Domain II is the 
elongated dimerization domain with the putative fusion peptide involved in virus-
mediated cell fusion (Rey et al., 1995; Roehrig et al., 1998; Allison et al., 2001). At 
the interface of these two domains is contained an N-octyl-β-D-glucoside molecule. 
The flexibility of this interface might be vital for the conformational changes required 
during maturation and fusion (Modis et al., 2003). The immunoglobulin-like domain 
III has been postulated to contain the receptor binding motifs (Crill et al., 2001) and 
is also an antigenic domain which is dependent on the integrity of a single disulphide 
bridge (Mandl et al., 1989). 
 
2.1.4.1 NS1 Protein 
Flaviviral NS1 is a 40-50 kDa detergent stable glycoprotein that exists as three 
discrete forms: membrane-associated, cell-surface associated and secreted form 
(Chambers et al., 1990a). The dimer is the major form of NS1 protein although a 
hexameric form of the secreted dengue virus type 1 NS1 protein was reported 
(Flamand et al., 1999). NS1 is secreted from infected mammalian cells but not from 
infected mosquito cells (Mason et al., 1989). 
 Although the functions of NS1 protein have yet to be fully elucidated, several 
lines of evidence have suggested that NS1 protein is involved in replication of viral 
RNA. Mutations in the glycosylation sites of NS1 have been shown to affect its 
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dimerization and subsequently impact virulence (Pryor et al., 1998). However, NS1 
dimerization is not an absolute requirement for its function (Hall et al., 1999). The 
NS1 protein has been shown to co-sediment with heavy membrane fractions 
containing RNA-dependent RNA polymerase (RDRP) activity from Kunjin virus-
infected cells (Chu and Westaway, 1992). Using mutagenesis of NS1 protein, a 
temperature sensitive mutant of NS1 protein was found which blocked accumulation 
of viral RNA (Muylaert et al., 1997). A yellow fever YF17D virus genome in which 
NS1 protein was deleted resulted in a defect in synthesis of minus-strand viral RNA 
compared to wild-type virus. This defect was complemented by supplying the NS1 
protein in trans (Lindenbach and Rice, 1997). The immunogenicity depends on the 
structure and form of NS1 where soluble dimers are more immunogenic and give 
higher protection than monomers and membrane-associated NS1 (Falconar et al., 
1991). 
 Finally, using immunolocalisation techniques, dengue and Kunjin NS1 
proteins have been shown to co-localize with NS3 protein, a component of the 
flaviviral replication complex (RC) and double stranded (ds) RNA in virus-induced 
membrane structures comprising vesicle packets (VP) of smooth membranes 
(Mackenzie and Young, 1996). 
 
2.2 The dengue threat 
With an annual estimate of 100 million cases of dengue fever, half a million 
cases of dengue haemorrhagic fever occurring in the world (Halstead, 1999) and a 30-
fold increase of cases for the past 50 years, dengue ranks as the most important 
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mosquito borne viral disease in the world (Pinheiro, 1997). This emergence is closely 
tied to population growth, rapid urbanization, ineffective control of Aedes aegypti and 
modern transportation (Gubler, 2002). The dengue situation is exacerbated by the 
lack of specific treatment, vaccine and proper animal models. Various vaccine 
strategies are being investigated to develop dengue vaccine candidates, but so far 
none has been approved for human use yet (Halstead et al., 2002, Stephenson, 2005). 
 
2.2.1 Dengue pathogenesis 
Dengue virus consists of four serotypes and is the aetiological agent of dengue 
fever which may progress to dengue haemorrhagic fever (DHF) and dengue shock 
syndrome (DSS). The main classical dengue fever features are biphasic fever which 
last for 2-7 days and rash. It is an acute febrile illness with other characteristics like 
abrupt onset of high fever, frontal headache, retro-orbital pain, myalgia, anorexia, 
abdominal discomfort, lymphoadenopathy and leucopenia. Hemorrhage and positive 
tourniquet test have also been reported in a few cases (Ahmed et al., 2001, Narayanan 
et al., 2002). The disease usually subsides after an average of 5 days with the 
disappearance of the virus from the blood. Infection of one serotype would induce 
life-long immunity against homologous but not heterologous serotype of the virus 
(Sabin, 1952). 
 Dengue hemorrhagic fevers usually follow secondary dengue infections, 
although primary infections are still possible, especially in infants. This could be due 
to maternally acquired dengue antibodies (Halstead et al., 2002). Dengue 
hemorrhagic fever is distinguished from DF by its acute vascular permeability with 
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abnormalities in haemostasis. Its severity is divided into four grades for ease of 
management (Table 2.1). Grade III and IV are clinical definitions of dengue shock 
syndrome (DSS). 
 The clinical features are plasma leakage, bleeding tendency and hepatic 
alteration. Capillary leakage develops rapidly over a period of hours when the 
symptoms of classic DF resolve. Pleural effusion, ascites and haemoconcentration are 
indicative of such leakage (Bhamarapravati et al., 1967). This can quickly progress to 
shock if volumic loss is not remedied with proper fluid therapy. The hemorrhagic 
manifestations range from a positive tourniquet test to spontaneous bleeding from the 
gastrointestinal tract or any body orifice. Haemoconcentration (haematocrit increased 
by more than 20%) and marked thrombocytopenia (platelet count <100 x 109/L) are 
two major characteristic features of DHF/DSS. Liver involvement in such infection 
would result in elevation of aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT). As such three organ systems, hematological, vascular and 
hepatic, are involved in the pathological changes in DHF/DSS. Dysfunction of these 
systems would either directly or indirectly, cause the manifestations of DHF/DSS 
(Burke et al., 1988). Dengue viral infections leading to neurological complications 
have also been reported (Garcia-Rivera et al., 2002). 
 
2.2.2 Hypotheses of dengue clinical features 
The main hypothesis to explain the clinical features of DHF/DSS is the 
antibody-dependent enhancement (ADE) while other hypothesis being conceptualized 
as ADE could not explain the phenomena of DHF/DSS fully. Other hypothesis  










Grading of Dengue Haemorrhagic Fever 
 
 
Grade I: Fever accompanied by non-specific constituitional symptoms. 
               The only haemorrhagic manifestation is a positive Hess test. 
 
 
Grade II: Spontaneous bleeding usually skin with or without bleeding from other 
orifices. 
                This is in addition to manifestation of grade I. 
 
 
Grade III: Cirulatory failure (rapid weak pulse with pulse pressure < 20mm Hg) but  
                 systolic pressure still normal. 
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includes a unifying hypothesis between ADE and T-cell activation and dengue viral 
virulence. 
 The concept of ADE of dengue viral replication in human mononuclear cells 
was formulated to explain the severe manifestations of DHF/DSS occurring in Thai 
children (Halstead et al., 1970). These children suffered from secondary dengue 
infection of a heterologous serotype. The ADE hypothesis postulates that the 
antibodies raised against one dengue serotype cannot neutralize but instead could 
enhance a secondary infection by another dengue serotype. The infectious complexes 
of virions and IgG antibodies would be internalized into monocytic cells via their Fcγ 
receptors, thereby increasing the number of infected monocytes. Subsequent lysis or 
immune clearance of such infected cells may lead to the release of vasoactive 
mediators and pro-coagulants (Rosen, 1986) (Fig 2.1). Sera obtained before infection 
from children who later developed DHF/DSS were also much more likely to 
demonstrate ADE in vitro (in human monocyte cells) than those who had only DF 
(Kliks et al., 1989). Babies less than 1 year old who acquired maternal anti-dengue 
antibodies are also susceptible to develop DHF/DSS following their first infection 
(Kilks et al., 1988). The association of DHF/DSS with secondary dengue virus 
infection is supported with a higher percentile of severe disease than primary 
infections. However, only 2-4% of such secondary infections progress to DHF/DSS 
(Guzman et al., 2002). Moreover, epidemiological studies in Peru, where over a 
period of 4 years (1993-1994), active surveillance for DF cases revealed that, in spite 
of secondary infection rates of up to 75%, no DHF cases have been detected (Watts et 
al., 1999). Therefore, ADE could not adequately explain the cases of DHF/DSS. 
Chapter 2: Survey of literature 
 
 12
Neither does ADE explain the molecular mechanism of DHF/DSS clinical 
manifestations. It is not known how the increase of dengue virus infection by 
enhancing antibodies leads to DHF/DSS and its effects remain to be elucidated. The 
causal relationship between ADE and DHF/DSS remains unverified due to the lack of 
proper animal model although higher viral counts had been observed in secondary 
infected non-human primates (Bielefeldt-Ohmann, 1997). 
 Immunopathogenesis in DHF has been proposed by Kurane and Ennis which 
unifies ADE with T-cell activation (Kurane et al., 1992; Rothman et al., 1999). 
Cross-reactive antibodies from the previous infection bind to virions without 
neutralization activity and enhance the entry of virus into monocytes. Thus, the 
number of viral infected monocytes increases. The level of T-cell activation is 
increased, due to the recognition of viral antigens via MHC class I and class II 
molecules by cross-reactive memory CD4 and CD8 T cells. These activated T cells 
produce pro-inflammatory cytokines such as IFN-γ, IL-2, TNFα and TNFβ, leading to 
the killing of the virus-infected monocytes. TNFα is also produced by activated 
monocytes due to viral infection and interaction with the T cells. The complement 
cascade is activated by the virus-antibody complexes (classical  
pathway of activation) as well as by several cytokines to release C3a and C5a proteins 
which also affect directly vascular permeability. The synergistic effects of IFN-γ, 
TNFα and activated complement proteins trigger plasma leakage of endothelial cells 
in secondary dengue virus infection (Fig 2.2). However, not all DHF/DSS cases are 
secondary infections and no observable sequelae are usually found which is not easily  
 
 













Figure 2.1. Proposed mechanism for ADE of viral infection 
 
Interaction between antibody and FcR (A), complement C3 fragment and CR 
(B) or C1q and C1qR (C) promotes virus attachment to cells. Antibody bound 
to a receptor-binding site of the viral protein induces a conformational change, 
which facilitates membrane fusion (D). Viral replication via ADE entry 
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reconciled due to the known tissue destructive effects of inflammatory cytokines 
(Rothman et al. 1999). 
 Virus virulence is the capacity of a virus to produce disease in a host. This is 
an alternative hypothesis to that postulated by ADE. The differential manifestations 
of DF, DHF and DSS may be due to the variants of dengue virus with different 
degrees of virulence. The risk of DHF/DSS is higher in secondary infections with 
dengue serotype 2 compared to the other serotypes (Rico-Hesse et. al, 1998, 1997). 
Structural differences have also been observed among viral isolates from DF and 
DHF patients in four viral proteins such as prM, E, NS4b and NS5 (Leitmeyer et al., 
1999). Of these four regions, E domain III has been shown to be one of the virulence 
determinants in mice-adapted dengue virus (Zulueta et al., 2006). 
It was also reported that high dengue viremia titre is related with disease 
severity. Higher viral titers were observed in patients with DSS than those with DF in 
dengue-infected Thai children. Apparently, viral load is also a contributing factor in 
the development of DHF/DSS (Vaugh et al., 2000).  
In 1953, Francis and co-workers proposed the doctrine of original antigenic 
sin to explain a phenomena they observed in influenza A infected individuals.  These 
individuals showed a higher titer of antibodies against the original infecting virus 
when they were infected with a new or another subtype of influenza A virus (Francis, 
1953) (Fig 2.3).  Halstead et al., (1983) suggested the existence of original antigenic 
sin due to observations in eight dengue infected Thai children. These children showed 
higher neutralizing antibody titers against the initial dengue serotype after they were 
infected with a different serotype in their secondary infection. The original antigenic  
































Figure 2.3. Phenomena of the original antigenic sin at the B cell level.  
Exposure to a cross-reacting influenza strain (strain 2) is more likely to recruit 
memory B cells that have been induced against the original influenza strain 
(strain 1) rather than naïve B cells specific for strain 2. The latter are more 
likely to be inhibited by persisting anti-strain 1 antibodies. ASC: antibody 
secreting cells. (Adapted from Lambert et al., 2005). 
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sin was also observed in dengue virus-specific CD8+ T-cell responses in Thai 
children (Mongkolsapaya et al., 2003). This process is where the host’s immune 
system preferentially uses the memory response from the previous infection when a 
similar pathogen is encountered. However, this response might be suboptimal to a 
newly mounted immune response and prevents the mounting of a more suitable 
optimal response. 
In these children, most of the dengue virus-specific T-cells were of low 
affinity to the infecting dengue serotype. They postulated that such T-cells were 
probably targeted against the initial dengue serotype and not the current infecting 
dengue serotype. The memory cells of the initial infection have a lower threshold for 
activation than naïve cells but are less effective in clearing the current infecting 
dengue serotype (Veiga-Fernandes, et al., 2000).Most of these T-cells were observed 
to be undergoing apoptosis and could contribute to the delay in viral elimination and 
increased immunopathology (Mongkolsapaya et al., 2003) . 
 
2.2.3 Treatment of dengue fever and dengue hemorrhagic fever 
 Currently, there are no effective drugs against the dengue virus and the 
management of dengue infections is mainly supportive. Early detection, proper 
management and hospitalization could reduce the rate of case fatalities (WHO, 1997).  
The only antipyretic drug used to control fever is paracetamol as other such 
drugs causes gastric irritation which might result in gastric bleeding. For fluid 
replacement therapy,  the WHO recommends using crystalloid solutions although 
initial resuscitation using colloids (dextran 70 or 3% gelatin) restores patient’s vitals 
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sooner than crystalloid solutions (Halliday et al., 1957; Wills, 2001). Antiviral drugs 
such as ribavirin and amantadine had been effective in inhibiting dengue virus 
replication in vitro. But these drugs have shown limited and contrasting results in 
dengue infected patients (Huang et al., 2001). Thus, there is an urgent need for 
dengue drug development. 
 
2.3 Flavivirus vaccines  
2.3.1 Licensed flavivirus vaccines 
 Today, only three flavivirus diseases have approved vaccines available. They 
are for yellow fever, Japanese encephalitis and tick-borne encephalitis. These three 
vaccines are produced by traditional methods of empirical attenuation of wild-type 
virus and formalin-inactivation to produce killed vaccines.  
Yellow fever (YF) is a fatal haemorrhagic fever transmitted to humans by 
Aedes mosquitoes (Monath, 1999). The wild type Asibi strain of YF virus was 
attenuated by multiple passage in chick embryo tissue, resulting in the current 17D 
yellow fever vaccine (Stokes et al., 1928). The 17D vaccine is the most successful 
flavivirus vaccine and had been administered to more than 400 million people, 
resulting in significant decrease in YF cases worldwide. A single dose of 17D vaccine 
could stimulate life long immunity and efficacy in 99% of the subjects (Monath, 
1999). Most of the adverse effects were observed in infants before age restriction was 
instituted. After which, the 17D YF vaccine was considered safe to be used as a 
vector (ChimeriVax™) for engineering new vaccines for flavivirus, cancer 
(McAllister et al., 2000) and malaria (Bonaldo et al., 2002).  
Chapter 2: Survey of literature 
 
 19
The most important cause of viral encephalitis in the Asia-Pacific region is the 
Japanese encephalitis virus (JEV) (Burke et al.,2001). The case-fatality rate ranges 
between 5 to 40% (Tsai, 2000). Currently, there are 3 vaccines against JEV used by 
the Asia-Pacific region. BIKEN (Osaka, Japan) produces one vaccine based on the 
wild-type Nakayama or Beijing-1 strains grown in adult mouse brains and China 
produces one vaccine based on the P3 strain grown in primary hamster kidney cells 
(WHO, 1998). These formalin-inactivated vaccines require two primary doses and a 
booster dose at 1 year, with subsequent booster every 3-4 years. The third vaccine 
against JEV is an empirically derived live attenuated vaccine designated SA14-14-2 
and is licensed to be used in China only. The immunization schedule consists of two 
doses at 1 and 2 years of age, with immunization efficacy greater than 95% after the 
first dose (Tsai et al., 1999). This vaccine is licensed to Glovax (Korea) for further 
development for the global market. 
The two main subtypes of tick-borne encephalitis (TBE) are the Central 
European encephalitis and Russian spring-summer encephalitis. The Russian spring-
summer strain is the more virulent strain causing most of the severe neurological 
problems, with a case-fatality rate of 20%. Both are antigenically related with up to 
96% in amino acid homology for the E protein. They are able to induce cross-reactive 
and highly-protective immune responses (Burket et al., 2001).  The vaccine used for 
TBE virus is a formalin-inactivated form of Austrian Central European encephalitis 
virus isolate grown in chick embryo cells by Baxter BioScience (Orth/Donau). 
Another vaccine is made from the European TBE virus by Behringwerke/Chiron 
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(Germany). Similar with all killed vaccines, multiple inoculation regimens are 
needed. 
 
2.3.2 Dengue vaccines  
According to Pediatric Dengue Vaccine Initiative (PDVI), the disease burden 
of dengue in South East Asia is 0.42 DALYs (disability adjusted life years) per 1000 
population. Premature mortality accounts for 52% of this calculation and 48% to 
acute morbidity. Despite causing 6% of clinical cases, DHF represents 68% of the 
disease burden and 67% of the treatment costs (http://www.pdvi.org). Thus, 
governments consider the feasibility of a dengue vaccine to be more cost-effective. 
The design of a safe dengue vaccine must address the problem of ADE due to 
pre-existing heterotypic dengue virus antibodies and the possible immune 
potentiation of the disease (Cardosa, 1998). This vaccine must also confer protection 
against all four serotypes and ideally should last throughout life (Trent et al., 1997). 
Advances in molecular biology and biotechnology, has led to many new strategies of 
vaccine design, such as chimerization of flaviviruses, specific mutagenesis of viral 
determinants of virulence. However, the traditional methods of formalin-inactivation 
and empirical attenuation are still being researched upon. 
 
2.3.2.1 Inactivated vaccine 
 Formalin-inactivated dengue vaccine was able to raise antibody in both Swiss 
ICR and BALB/c mice to neutralize the dengue virus serotype 2 (Putnak et al., 
1996a). Despite being attempted for more than 60 years, the inactivated virus is 
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plagued by poor yield due to production methods. This was overcome by growing 
these viruses in either fetal rhesus lung diploid or Vero cell culture which makes such 
vaccine economically viable again (Putnal et al., 1996a; 1996b). 
 
2.3.2.2 Live attenuated vaccine 
  The development of live attenuated tetravalent dengue vaccine is one of the 
strategies to obtain a vaccine against dengue viruses. Production of such vaccine is by 
using natural or chemical mutagens and serially passages them in cell cultures to 
attenuate the virus (Eckels et al., 1984). Currently, only two formulations of live-
attenuated vaccine candidates are in various stages of clinical trials.  
The first was developed by Mahidol University, Bangkok, Thailand and 
licensed to Aventis Pasteur, Lyon, France. The attenuation process is by serial 
passaging of Dengue serotype 1, 2 and 4 in primary dog kidney cell (PDKC) cultures 
while serotype 3 underwent the same process in primary African green monkey 
kidney cells (Bhamarapravati et al., 2000). Sero-conversion of the ten volunteers who 
received a single dose of tetravalent vaccine ranged from 30 to 70% for the four 
serotypes. Three of four volunteers showed a high titre of neutralizing antibody 
response against all four serotypes after the third dose (Chaturvedi et al., 1994). 
Despite the lack of serious adverse effects and high seroconversion rates, there were 
16 breakthrough infections by dengue virus serotype 1, 2 and 4 resulting in mild 
illness (Halstead et al., 2005). 
The second formulation of live attenuated dengue vaccine was developed at 
the Walter Reed Army Institute of Research (Silver Spring, MD, USA) and is 
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licensed to GlaxoSmithKline, Rixensart, Belgium. All four dengue viruses were 
serially passaged in PDKC culture and the final formulation produced in fetal lung 
cells of the rhesus monkey. After 2 doses, 80-90% of the adult volunteers developed 
neutralizing antibodies against all four serotypes of the virus (Halstead et al., 2002). 
For both the Mahidol/Aventis and Walter Reed Army Institute of 
Research/GlaxoSmithKline attenuated virus, immnuo-interference by each of the 
attenuated virus hampers the raising of equivalent levels of immunity against each of 
the 4 serotypes. Optimization of dose-ratio and vaccination schedule must be carried 
out to improve immunity against all four serotypes of dengue virus (Sun et al., 2006). 
 
2.3.2.3 Chimeric virus vaccine 
 The potential of creating chimeric flaviviruses was put forward by Rice et al. 
(1999) when they were able to produce a viable YF 17D (YF17D) virus strain from 
its full-length cDNA. Thus, chimeric flavivirus vaccine can be created by 
incorporating attenuated mutations or deletions of viral protein genes for the target 
antigen on the backbone of the YF17D vaccine strain (Rice et al., 1999). Using the 
YF17D vaccine virus, the ChimeriVax™ platform was created and was able to 
express the prM and E proteins of dengue in a chimeric yellow fever/dengue virus 
(ChimeriVax-DEN). The ChimeriVax-DEN was also able to protect immunized 
BALB/c mice from lethal dengue encephalitis (van der Most et al., 2000). Another 
ChimeriVax-DEN targeting 4 serotypes of dengue was constructed by Acambis, Inc., 
Cambridge, Massachusetts, USA (Guirakhoo et al., 2002). This chimeric virus 
vaccine showed poor infectivity in mosquitoes but was still protective in non human 
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primates (Guirakhoo et al., 2004). Initial phase I trials reported 100% neutralizing 
antibody seroconversion following the administration of the chimeric virus vaccine 
candidate in 48 adult volunteers (Halstead et al., 2005). 
 The four attenuated dengue virus vaccine strains developed by Mahidol 
University, Bangkok, Thailand also showed potential as a platform for chimeric virus 
vaccine candidates. Using the attenuated dengue virus PDK-53 strain of serotype 2 
(CDC, USA) and Mahidol University were able to develop a vaccine targeting 
dengue serotype 1 (DEN-2/DEN-1). It was shown to be protective against dengue 
serotype 1 in outbred mice ICR when they were intracranially challenged (Huang et 
al., 2000). Chimeric virus against serotype 3 and 4 has also been synthesized using 
such the PDK-53 platform. Both mice and rhesus monkey have raised neutralizing 
antibodies following immunization with a tetravalent mixture of the above mentioned 
PDK-53 chimeric vaccines (Huang et al., 2003). This vaccine candidate is licensed to 
Aventis Pasteur, Lyon, France and is undergoing further test in non human primates. 
 
2.3.2.4 DNA vaccine 
 DNA vaccination is the direct injection of pure plasmid DNA to raise the 
immune response against the antigen expressed (Wolff et al., 1990; Tang et al., 
1992). This discovery had been directly translated to attempt to raise immune 
response against dengue 2 virus by Kochel et al. (1997). They have shown that 
BALB/c mice intradermally inoculated with prM and E expressing plasmid where 
able to develop antibodies against dengue serotype 2 virus. But only 60% were able 
to survive a lethal intracerebral challenge (Kochel et al., 1997). A similar experiment 
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was carried out targeting dengue serotype 1 in non human primates. The Aotus 
monkeys were observed to be protected from viraemia for up to six months and the 
highest antibody response was observed to be those co-injected with  granulocyte 
macrophage colony stimulating factor (GM-CSF) (Raviprakash et al., 2001). 
  
2.3.2.5 Recombinant subunit vaccine 
 With the rapid advancement in molecular biology techniques, the 
development of recombinant subunit vaccines for different viruses has become more 
prevalent. Majority of the focus in dengue virus had been on recombinant E and NS1 
proteins, while some have tried other immunogenic proteins of dengue virus. These 
immunogens of dengue can be expressed in various expression systems (Table 2) 
such as bacterial (Srivastava et al., 1995; Sugrue et al., 1997; Simmons et al., 1998; 
Jaiswal et al., 2004), yeast (Sugrue et al., 1997; Bisht et al., 2001; 2002), mammalian 
(Konishi et al., 2002), viral (Jaiswal et al., 2003) and insect systems (Lai et al., 1989; 
Feighny et al., 1992; Men et al., 1991; Putnak et al., 1991; Eckels et al.,1994; 
Staropoli et al., 1996; 1997; Kelly et al., 2000). These systems have shown varying 
degrees of protection in mice with the recombinant proteins, and optimization is 
required especially with regards to the folding of proteins such as domain III of E 
protein (Jaiswal et al., 2004) (Table 2.2). 
 The flaviviral E protein is the only viral protein to elicit neutralizing 
antibodies against flaviviral infection and is sufficient to protect against infection 
(Brinton et al., 1998; Kliks et al., 1988). The neutralization activity of IgG2a subclass 
consistently showed the greatest ability to neutralize dengue viruses (Smuchny et al., 
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ab, antibody; C, structural C protein; CHO, Chinese hamster kidney; E, envelope glycoprotein; M, structural membrane protein; Nab,neutralizing antibody; NA, 
not known; NHP, nonhuman primate; prM, premembrane protein; sf9, Spodoptera frugiperda cells; NS, nonstructural protein 
 
Table 2.2: Recombinant dengue vaccine. Adapted from Chaturvedi et al.,2005. 
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1995). With the elucidation of the 3D structure of E protein in TBE and dengue virus 
(Rey et al., 1998; Modis et al., 2003), mapping of neutralizing epitopes of flavivirus 
could be carried out. Using monoclonal antibodies, phage display techniques and 
synthetic peptides, the neutralizing epitopes were found to be located within the 
domain III (Crill et al., 2001; Beasley et al., 2002) and domain II (Roehrig et al., 
1998) of E protein. With pan-dengue neutralizing monoclonal antibody 4E11, 
Thullier et al (2001) was able to identify the conserved regions amongst the four 
serotypes to be residue 310-314 of glycoprotein E. Other than B-cell epitopes, E 
protein also contains helper- and cytotoxic-T cell epitopes (Mathews et al., 1991; 
1992; Rothman et al., 1996).  Thus, the E protein is able to elicit both cellular and 
humoral immune responses, making it a candidate for dengue vaccine development. 
Recent studies in non human primates have also shown that immunization with 
domain III of the E protein is protective against viral challenge (Hermmida et al., 
2006). 
The NS1 protein is highly immunogenic and can induce protection in 
experimental animals against flaviviral infections (Schlesinger et al., 1987; Brinton et 
al., 1998). The anti-NS1 antibodies are non-neutralizing and are postulated to have 
complement-fixing activity, which enables them to kill infected cells (Iacon-Connors 
et al., 1996; Schlesinger et al., 1987; Falgout et al., 1990). Both cell culture and in 
vivo experiments indicated that protection by anti-NS1 antibodies was provided via 
an Fc receptor-dependent mechanism which could only be stimulated by the Fc 
portion of IgG2a and IgG2b antibodies (Schlesinger et al., 1993; 1995). B-cell 
epitopes have been mapped on dengue virus NS1 to amino acids residues 25-33, 33-
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50, 61-69, 111-121, 135-145, 173-177, 299-309 and 320-345 (Falconar et al., 1994; 
Garcia et al., 1997; Huang et al., 1999).T cell epitopes have also been found in the 
NS1 protein (Rothman et al., 1996). Antibodies against NS1 have been shown to be 
protective from viral infection (Mellado-Sanchez et al., 2005) and NS1 DNA vaccine 
can protect against intracerebral challenge in mice (Costa et al., 2006). 
 
2.4  Lactococcus lactis - Classification 
Lactococcus lactis is a Gram-positive non-sporulating, non-motile, facultative 
anaerobe bacterium. They are cocci in pairs and short chains, typically 0.5 - 1.5 µm in 
length. They belong to a group of bacteria known as the lactic acid bacteria (LAB) 
(Nester et al., 2004). Three different categories of LAB are widely studied in details 
for use as vaccine carriers, Lactococcus lactis MG1363, Streptococcus gordonii and 
members of Lactobacillus eg. Lactobacillus plantarum (Mercenier et al., 2001). 
LAB are a phylogenetically heterogeneous group of Gram-positive cocci or 
bacilli. These bacteria are widely used traditionally in the food industry for 
production and preservation of fermented products. Thus, they are considered ‘safe’ 
with a GRAS (Generally Recognized As Safe) status (Pouwels et al., 1998). This is in 
contrast to other live vaccine delivery vehicle such as attenuated Salmonella and 
Escherichia coli (Norton et al., 1994). Unlike the rest of the LAB, Lactococcus lactis 
is non-colonizing and non-invasive (Iwaki et al., 1990; Dutot et al., 1993; Norton et 
al., 1994). The innocuous nature and the low intrinsic immunogenicity of L. lactis 
ensures its ability to be used repeatedly for vaccination (Norton et al., 1994). 
 




2.5 Lactococcus lactis as a mucosal vaccine delivery vehicle 
2.5.1 Mucosal vaccines 
 The main aim of mucosal vaccination is to prevent the initial colonization and 
infection by infectious pathogens. This is accomplished by the local mucosal immune 
response, including the production of IgA antibodies. IgA antibody promotes the 
entrapment of antigens or pathogens in the mucus, preventing direct contact of 
pathogens with the mucosal surface. This is known as ‘immune exclusion’ (Phalipon 
et al., 2002). Moreover, the antigen specific IgA antibody response elicited by 
mucosal immunization not only protects the immunized host from the pathogen but 
can also eliminate the healthy carrier condition. The healthy carrier condition may 
result in the subsequent transmission of infections to non-immunized individuals (De 
Magistris, 2006). 
In the mucosal-associated lymphoid tissues (MALT), the lymphoid tissues are 
normally in aggregated and non-encapsulated forms. They are located in lamina 
propria and submucosal layer of the gastrointestinal, respiratory and genitourinary 
tracts (Roitt et al., 2001). The intestine contains lymphoid elements such as Peyer’s 
Patches (PP), enriched with multifold (M) cells. The deep invagination of the 
basolateral plasma membrane of the M cells forms pockets that concentrate B cells, T 
cells, dendritic cells (DCs) and macrophages in the submucosal layer (Langridge, 
2000). M cells are able to endocytose antigens from the mucosal surfaces, and 
transport them into the underlying follicle where the antigen presenting cells (APCs) 
are located (Roitt et al., 2001).  Another mechanism of antigen sampling is by the 
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DCs which are able to migrate into spaces between epithelial cells and to the outer 
limit of the epithelium. Foreign antigens are directly sampled from the luminal 
compartment (Holt et al., 1990; Miller et al., 1992). The immunization of one 
mucosal site results in the secretion of the same specific IgA antibodies at other distal 
mucosal sites. This phenomenon is known as ‘common mucosal immune system’ 
(Mestecky, 1987). This is due to the expression and up regulation of ‘homing 
receptors’ and redundant counter-receptors which guide the activated lymphocytes 
back to the mucosa (Kunkel et al., 2003).  For example, mucosa-activated IgA 
secreting B cells express CCR10 which is the receptor of the CCL28 chemokine. 
CCL28 is secreted by epithelial cells of the small and large intestines, salivary glands, 
tonsils, respiratory tract and lactating mammary glands. Thus, the B cells can be 
attracted to these tissues (Kunkel et al., 2003).   
 In addition to eliciting IgA antibody responses, mucosal vaccination is able to 
trigger systemic IgG responses against the antigen (Service, 1994) (Table 2.3). 
Induction of systemic IgG can be due to two mechanisms. Upon antigen uptake, the 
activated mucosal DCs are able to migrate to the lymph nodes and spleen where they 
present the processed antigen to naïve T cell and trigger the adaptive immunity 
(MacPherson et al., 1999). The second mechanism involves a portion of the B cells 
being activated in the mucosa and expressing the peripheral homing receptors α4β1-
integrin and leukocyte(L)-selectin allowing them to migrate to the regional lymph 
nodes (Kunkel et al., 2003). Other than humoral immunity, cellular mediated 
response could be stimulated in the form of helper CD4+ T cells and CD8+ cytotoxic 
T lymphocytes which is important in combating intracellular pathogens like viruses. 
Systemic IgG and local IgA response following mucosal immunization 
Immunogen Route               Specific serum IgG  Responses of specific IgA antibodies* 
 
Small         Large          Cervix/    Salivary     Nasal  
intestine     intestine      vagina     glands        cavity 
Reference 














Nasal                  +++++ 
 
Oral                    +++ 
 
Rectal                 +++ 
 
Vaginal               ++ 
 
 
Oral                     ++  
 
Rectal                  +  
 
Oral                     ++++ 
 
Colonic               ++++ 
 
Vaginal               -    
ND              ++              +++         -                 +++ 
 
++++           ++              +/-           +                 - 
 
ND              ++++          -              +/-               ND 
 
ND              +/-              +++         +/-               ND 
 
 
+++             -                  +/-           +/-               - 
 
+/-               ++               -               -                  +/- 
 
+++             ++               -               ND              + 
 
ND              +++            ND           ND               - 
 
ND              ND             +++          ND               - 
Kozlowski et al.,1997 
Wassen et al., 1998 







Kantele et al.,1998 
Forrest et al.,1990 
 
 
Ogra et al.,1969,1973 
*Responses are based on geometric mean post-vaccination increases in specific antibody corresponding to: +++++,>50-fold; ++++,25-49.9 fold; +++, 10-24-
fold; ++, 5-9.9-fold; +,2.5-4.9-fold; +/-,.2.5-fold in a minority of vaccine recipients;-,<2.5-fold in all vaccine recipients. ND, not determined 
Table 2.3: Systemic IgG and local IgA response following mucosal immunization. Adapted from Neutra et al.,2006 
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 Thus, mucosal vaccines can activate both arms of the adaptive immune system (De 
Magistris, 2006). 
The administration of mucosal vaccines provides some practical advantage 
like being non-invasive and needle-free. This would ensure compliance due to ease of 
distribution and administration without the need for trained personnel. It can also 
avoid blood transmissible infections due to needle re-use or needle stick injury 
(Levine, 2003). Due to limited understanding of mucosal immunity, complex 
measurement of mucosal response to vaccine dose ratio, there are only a few mucosal 
vaccines approved for human use. The approved vaccines include vaccines against 
poliovirus (Modlin, 2004), Salmonella typhi (Levine, 2000), Vibrio cholera (Levine, 
2000), rotavirus (Kapikian , 1996) and influenza virus (Belshe, 1998). 
   
2.5.2 Lactococcus lactis as antigen delivery vehicle 
 Formerly known as Streptococcus lactis, L. lactis has been widely studied as 
an antigenic or therapeutic protein delivery vehicle to the mucosal surface. Coupled 
with a GRAS status, this vehicle could potentially be used to elicit specific mucosal 
and systemic immune responses (Wells et al., 1993). Unlike other LAB, L. lactis does 
not colonise and has a low innate immunogenicity enabling its repeated use for 
booster effect without tolerance (Norton et al., 1994). The low proteolytic activity 
against self-produced heterologous protein makes it analogous to inert microparticles 
or antigen-loaded liposomes. Another advantage L. lactis has over another widely 
studied LAB - Lactobacillus sp., is its ease to genetic manipulation (Wells et al., 
1993).   
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 Expression systems were designed to direct synthesized proteins to the 
cytoplasm, membrane anchored (with a LPXTG motif) or secreted (using signal 
peptide of Usp45) out of the cell (Reveneau et al., 2002; Raha et al., 2005). Various 
inducible (nisin-inducible) and constitutive lactococcal promoters have also been 
used to increase the yield of the heterologous protein produced (Wells et al., 1995). In 
order to circumvent the need for use for antibiotics the two system using threonine- 
and pyridmidine-auxotrophs L. lactis were also introduced (Sorensen et al., 2000; 
Glenting et al., 2002).  L. lactis was also reported to be an efficient vehicle for tetanus 
toxin fragment C via both nasal and oral routes of inoculation. The nasal route was 
observed to be more efficient in protection against lethal challenge against tetanus 
toxin (Norton et al., 1995). To date, many studies have described the use of L. lactis 
as a vehicle to deliver several antigens of pathogenic organisms such as SARS-
coronavirus (Pei et al., 2005), Rotavirus vp7 antigen (Perez et al., 2005), human 
papillomavirus type 16 E7 antigen (Bermudez-Humaran et al., 2004), Human 
immunodeficiency virus Env (Xin et al., 2003), Enterovirus 71 VP1 (Raha et al., 
2005), Helicobacter pylori urease subunit B (Lee et al., 2001), Brucella abortus 
L7/L12 antigen (Riberio et al., 2002) and malarial MSP-1 (Zhang et al., 2005). 
Therapeutic proteins such as interleukin-10 have been used to treat murine colitis 
(Steidler et al., 2000) or in combination with antigens (Steidler et al., 1998). Thus, L. 
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2.5.3 LAB as immunomodulators 
 LAB strains have been shown to be able to interact with the host immune 
system. The main immune response induced by oral administration of LAB is 
hyporesponsiveness which is also known as oral tolerance. This tolerance is due to 
the induction of cytokines such as IL-10 or transforming growth factor β (TGF β) or 
by clonal deletion (Elson et al., 1996). Such tolerance is usually induced by T-cell 
dependent antigens with the presence of CD8+ T cells required for this process 
(Mowatt, 1987; Challacombe et al.,1980). Dosage determines the ability of LAB to 
result in tolerance.  
LAB have also been shown to potentiate some immune responses. L. 
plantarum has been found to induce a delayed type hypersensitivity when 
administered intraperitoneally (Bloksma et al., 1979). Intraperitoneally administered 
Lactobacillus casei was demonstrated to increase the phagocytic activity of 
macrophages and monocytes (Saito et al, 1983; Kato et al., 1983). This was also 
observed in mice orally administered with Lactobacillus acidophilus, Lactobacillus 
delbrueckii and Streptococcus thermophilus (Perdigon et al., 1986). But unlike 
Propionibacterium acnes and Mycobacterium bovis, Bacillus Calmette-Guerin 
(BCG), there was no hepatomegaly or splenomegaly which is common side effects of 
these immunomodulators (Yasutake et al., 1984).  Kupffer cells, the immune cells of 
spleen and lungs and peritoneal macrophages were activated by administration of 
Lactobacillus casei (Hashimoto et al., 1985). Similarly, L. lactis has been shown to 
increase the number of immune cells responsible for inflammatory response such as 
macrophages, neutrophils and eosinophil (Perdigon et al., 2001). The authors 
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postulated that L. latis interacts with the epithelial cells of the small intestine or the 
follicle associated epithelium in Peyer’s patches.  
 
2.6 Animal models 
2.6.1 Mouse models for dengue virus 
 The Dengue virus is an intriguing virus and the immune mechanisms involved 
in the pathogenesis of DHF/DSS remains an enigma. Despite the dengue-infected 
non-human primates result in viremia, they do no become ill like humans (Halstead et 
al., 1971; Marchette ,et al., 1972; Schiavetta et al., 2003). With the limited use of 
non-human primates due to ethical and financial reasons, the development of small 
animal models has become necessary for vaccine and antiviral studies (Atrasheuskaya 
et al., 2003; Shresta et al., 2004). An overview of some of the murine models such as 
inbred, knockout and humanized SCID strains for dengue virus study is presented 
below. 
 
2.6.1.1 Inbred mouse strains 
 The inbred strains used as dengue murine models are BALB/c, C57BL/6 and 
A/J mice. BALB/c mice peritoneally infected with Dengue virus type 2 were 
observed to have significant hepatic injuries and elevated alanine aminotransferase 
and aspartate aminotransferase. These observations mimic the liver alterations in 
dengue infected humans (Paes et al., 2005). Atrasheukay and co-workers (2003) 
infected 4-weeks old BALB/c mice with mouse brain-adapted Dengue virus which 
develop severe anaemia, thrombocytopenia, non-overt haemorrhage and shock. They 
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were also able to reduce mortality in fatally infected mice with anti-TNF-α antibodies 
(Atrasheukay et al., 2003).  
 A/J mice inoculated intravenously with non-adapted dengue virus presented a 
transient thrombocytopenia and produced anti-platelet antibodies. These antibodies 
were postulated to contribute to DHF in human patients. Thus, the A/J mice are 
valuable model for immunopathogenicity study of dengue infection. The BALB/c or 
C57BL/6 mice were less sensitive to the strain of virus inoculated (Huang et al, 
2000a; 2000b). The higher susceptibility of A/J mice could be due to a lower 
lymphoid, granuloid, monocytoid and NK cell count as compared to C57BL/6 mice 
(Miller et al., 1998; Whyte et al., 1998). However, dengue virus was not able to 
replicate to detectable levels in blood serum of any of those inbred strains. 
 
2.6.1.2 Knockout strains 
 Recently, the AG129 mouse strain was studied by several groups for its use as 
a potential dengue virus animal model. This strain lacks both α/β-interferon and γ-
interferon receptor genes (Johnson et al., 1999; Shresta et al., 2004; 2006). Unlike 
inbred strains, dengue infected AG129 showed detectable virus titres in the serum, 
brain and spleen (Johnson et al., 1999). Shresta and co-workers (2006) demonstrated 
that infected AG129 mice had increased vascular permeability. This observation is a 
significant hallmark of DHF/DSS in humans. Paralysis due to neuronal abnormalities 
was observed in infected mice, which has been described in rare cases of DHF/DSS 
in humans (Solomon et al., 2000). 
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2.6.1.3 Humanized SCID strains 
 Severe combined immunodeficiency mice grafted with human cells are 
susceptible to dengue viral infection as the virus is able to replicate more efficiently. 
The main cell targets for viral infection and replication are DC, macrophages and 
hepatic cells (Kwan et al., 2005; Wu et al., 2000). Thus, reconstituting such cells in 
SCID mice would enable initial replication which results in higher viraemia. The two 
basic models were the human erythroleukemia cell line (K562) and human 
hepatocarcinoma cell line (HepG2) engrafted SCID mice (An et al., 1999; Lin et al., 
1998). These engrafted cells have been shown to be permissive for infection and 
replication of dengue virus (Knowles et al., 1984). Dengue clinical symptoms like 
thrombocytopenia, prolong thromboplastin time and increased hematocrit, were 
observed in paralyzed dengue-2 infected HepG2-SCID mice but were not related to 
the immune responses to viral infection (An et al., 1999). K562-SCID mice 
inoculated with dengue type 2 developed paralysis and die (Lin et al., 1998). 
However, the lack of an immunocompetent background makes these two models 
unsuitable for vaccine and antiviral studies.  
 In a recent report, Bente and co workers were able to engraft human cord 
blood haematopoietic progenitor cell (CD34+ cells) in the immunodeficient 
environment of non-obese diabetic (NOD)-SCID mice. With the ability to mount a 
primary and secondary immune response similar to humans, the humanized NOD-
SCID mice were able to develop clinical signs of DF as in humans when infected by 
virus-infected mosquitoes (Bente et al., 2005). 
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2.6.2 Mouse models for the study of Lactococcus lactis as vaccine vehicle 
 In the immunity against infectious pathogens, Th1 cells are involved in 
eradicating intracellular micro-organisms like viruses, while Th2 cells protects the 
host from extracellular pathogens such as helminthes. Thus, Th1-prone C57BL/6 (H-
2b) and Th2-prone BALB/c (H-2d) mice are widely used for vaccine studies (Gorham 
et al., 1996; Reiner et al., 1995). It is also observed that for protection experiments 
BALB/c and C57BL/6 are better to be used in parallel (Zhang et al., 2005). 
 Enteric anti-lactococcal secretory IgA antibodies have been detected in 
control, non-infected mice with BALB/c showing a higher titer than C57BL/6, 
indicating that these animals either have been exposed naturally to L. lactis or 
produce antibodies against other LAB which cross-react with L. lactis (Norton et.al., 
1994). Moreover, an increase in anti-lactococcal class switching from IgM to IgG as 
the mice get older might be due to the continual exposure to environmental L. lactis 
or cross reactive LAB.  In this study, L. lactis was also reported to be a suitable 
vaccine vehicle with optimal dosage of 1 x 108 bacteria for oral inoculation in 
eliciting the optimal amount of anti-lactococcal antibodies. But any dosage below or 
above the optimal dose would result in low amounts of anti-lactococcal antibodies 
due to under dosing and immune tolerance respectively (Norton et al., 1994). In 
conclusion, BALB/c or C57BL/6 mice have been widely used for studies using L. 
lactis as vaccine vehicle depending on the type of pathogen targeted for protection 
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Chapter 3: Materials and Methods 
 
3.1 Cell culture 
 BHK-21 (baby hamster kidney ATCC number CCL-10) cells were grown and 
maintained in 75 cm2 tissue culture flasks in RPMI 1640 (Gibco, Boston, MA, USA) 
supplemented with 10% fetal calf serum (FCS), 2% HEPES and 1.5% sodium 
bicarbonate. 
 When the cells were confluent, usually within 3-4 days, the cell monolayer was 
rinsed with 8 ml of PBS to remove the dead cells, and dislodged by the addition of 1ml of 
pre-heated (37oC)  1 X trypsin/versene solution (Appendix 1.1.3) . 3ml of growth 
medium was added to dilute the trypsinized cells and split in a ratio of 1:4. 
3.2 Preparation of Dengue 2 Virus Stock 
 BHK-21 monolayers were inoculated with 1ml of dengue virus type 2, New 
Guinea C (DEN2 NGC) strain which contains approximately 105 PFU. Virus adsorption 
was carried out by incubating the flasks at 37 oC for 1 hour with rocking at 15 min 
intervals. Following adsorption, 12 ml of complete growth medium (as described above) 
were added and the flasks were incubated at 37 oC for 10-14 days. The culture 
supernatant was then harvested and centrifuged at 10,000 g for 20 min to eliminate 
cellular debris. The resulting supernatant was aliquoted and stored at -80  oC, as the virus 
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3.3 Viral Quantitaion Using Plaque Assay 
3.3.1 Determining of viable cell with hemocytometer 
 Trypan blue is one of several stains used for dye exclusion procedure for viable 
cell counting. This method is based on the principle that live cells do not take up certain 
dyes whereas dead cells do and appear blue under the microscope. 
 Equal volumes of the trypsinized cell suspension and 0.4% trypan blue solution 
(Sigma) were mixed together. This mixture was allowed to stand for 5 min at room 
temperature, then loaded into the chambers of the haemocytometer and observed under 
the microscope. Starting with one chamber of the haemocytometer, all the viable cells 
were counted in the 1 mm center square and the four 1 mm corner squares. The cells on 
top and those that touched the middle line of the perimeter of each square were counted 
while those touching the middle line at the bottom and right sides are not. The procedure 
was repeated for the other chamber. Each square of the haemocytometer with the cover 
slip in place represented a total volume of 0.1 mm3 or 10-4 ml. Thus, the subsequent cell 
concentration per ml is determined as follows:  
Viable cells per ml = the average count per square x dilution factor of 2(dilution factor 
due to addition of Trypan blue)  x 104  
 
3.3.2 Plaque assay 
 Two days prior plaque assay, BHK cells were seeded onto 24-well plates (Nunc, 
Roskilde, Denmark) at 2.5 x 105 cells per ml. Ten-fold serial dilutions of the virus (10-1 to 
10-6) were performed in RPMI 1640 culture medium. 100μl of undiluted and diluted virus 
suspensions were then added to each well and viral adsorption was carried out at 37oC, 
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5% CO2 for 1.5 hrs. Triplicates were done for each dilution. 1 ml of 1% (w/v) 
carboxymethyl cellulose (Appendix 1.2.1) in RPMI supplemented with 2% FCS 
(Appendix 1.1.1) was then added to each well and the cells were incubated at 37 oC, 5% 
CO2 for 6 days. Visualization of plaques was achieved by fixing the cells with 20% 
formaldehyde solution followed by staining with approximately 200 μl of 0.5% crystal 
violet dissolved in 37% formaldehyde (Appendix 1.2.3) to each well. After thorough 
rinsing with water, the plates were dried and the plaques were scored. 
 
3.4 Plaque reduction neutralization test (PRNT) 
 The presence of neutralizing antibodies in the mouse sera was determined by 
PRNT. Each of the mouse sera was heated at 56 oC for 30 min to inactivate complement. 
2-fold serial dilutions of the sera (1:10 to 1: 320) were prepared in RPMI 1640 in 24-well 
plates. Each dilution was incubated with an equal volume containing 30PFU of dengue 
virus NGC strain. The virus-serum mixture was incubated at 37 oC for 1 hr with rocking 
every 15 min. Each mix (100μl) was transferred onto BHK monolayers grown in 24-well 
plates, and incubated at 37 oC for 1.5 hrs. The mix was decanted and subsequently 
processed according to the plaque assay described in section 3.3.2. The percentage of 
plaque reduction was calculated relative to the virus control without serum. The 
envelope-specific monoclonal antibody 3H5 (#8702, Chemicon International, USA) 
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3.5 Bacterial strains and cultures 
3.5.1 Bacterial strains 
The L. lactis strains and plasmids used in this study are listed in the following 
table 3.1. 
 




Lactococcus lactis MG1363 Derivative of L. lactis 
subspecies cremoris 
- Pasteur Institute 
of Lille (Dr C. 
Grangette) 
LLWE Lactococcus lactis MG1363 
transformed with pMG36E 
Erythromycin Lin W. 
(unpublished) 











pMGE-EDIII pMG36E derivative with 
SacI-PstI E domain III 
fragment 
Erthromycin Lin W. 
(unpublished) 
 
Table 3.1: L. lactis strains and plasmids 
 
 
3.5.2 Media and growth conditions 
All L. lactis strains were grown at 30°C overnight in fresh Difco™ M17 broth 
containing 0.5% glucose (GM17) without shaking, or on GM17 agar. 10 µg/ml of 
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3.6 Immunization and persistence studies in mice 
 
3.6.1 Immunization studies 
3.6.1.1 Mouse strains 
 Two different strains of mice were used for both oral and nasal immunization 
studies, namely BALB/c and C57BL/6. They were purchased from Biological Resource 
Centre, Biopolis, Singapore. Groups of four to six 5-6 week old female mice were 
immunized.  
 
3.6.1.2 Nasal immunization 
  Either recombinant L. lactis pMG36e/EDIII (LLWE-EDIII) or L. lactis pMG36E 
(LLWE) were cultured at 30oC for 18 hours and harvested by centrifugation at 3,000 g 
for 10 mins at 4oC. The cell pellets were washed three times with cold PBS, and then re-
suspended in PBS to obtain 108 CFU in 20μl (1010 CFU/ml) for each mice. BALB/c mice 
were anaesthesized using the anaesthetic cocktail (6% valium+ 10% atropine+ 20% 
ketamine) as described previously (Alonso et al, 2001) and C57BL/6 mice were 
anaesthesized using the same cocktail but with 3% valium instead of 6%. The sedated 
animals were inoculated with either LLWE-EDIII or LLWE suspensions using a 
micropipette and dropping 10 μl into each nostrils. This procedure was repeated at 14, 28, 
70 and 84 days after the first administration (Fig 3.1A).  This protocol was adopted from 
Mannam et al. (2004) with modifications for the third and forth boost. 
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3.6.1.3 Oral administration 
 Non-sedated animals were inoculated with either recombinant LLWE-EDIII or 
LLWE harvested and re-suspended in PBS supplemented with 0.1% glucose at a 
concentration of 5x1010 CFU/ml. Water was restricted an hour before oral inoculation. 
For each mouse, 200μl of the bacterial suspensions were administred via intragastric 
gavage (Popper and Sons Inc, New York, USA). The bacteria suspensions were given on 
3 consecutive days (0, 1, 2 days). A booster immunization was given at 14, 15 and 16 
days, a second booster was given at 28, 29 and 30 days, a third booster was given at 70, 
71 and 72 days and a forth booster was given at 84, 85 and 86 days (Fig 3.1B).  This 
protocol was adopted from Lee et al. (2001) with modifications for the third and forth 
boost. 
 For the positive control, mice were injected intraperitoneally (ip) with 105 PFU of 
heat inactivated DEN 2 NGC. The inactivated virus was mixed with an equal volume of 
CFA (complete Freund’s adjuvant) (Sigma-Aldrich, Inc. St Louis, Missouri, USA) for the 
priming dose, or with IFA (Incomplete Freund’s adjuvant) for the booster dose, and 
100μl of the mixture was injected. 
 
3.6.1.4 Collection of sera 
Blood was collected from sedated mice by retro-orbital puncture on day 42, 56, 
69, 77 and 91 for both nasal and orally inoculated mice. Blood was allowed to clot 
overnight at 4 oC before centrifuging the specimens at 800 rpm for 10 min 4 oC. The 
serum was then transferred to a fresh collection tube and stored at -20oC until use. 
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3.6.1.5 ELISA  
 The titres of anti-EDIII and anti-lactococcal antibodies were measured by ELISA 
using purified envelope domain III protein (EDIII) and whole cell Lactococcus lactis as 
the coating antigen respectively. A culture of Lactococcus lactis was washed as stated in 
3.6.1.1, resuspended in ice-cold PBS and sonicated five times for 45 sec each with 
intervals of 30 sec. The preparation was kept on ice during the sonication. Total protein 
concentration was estimated using NanoDrop® ND-1000 spectrophotometer (NanoDrop, 
Wilmington,DE, USA). 
Purified EDIII or sonicated L. lactis were coated onto the 96-well plates (Corning 
costar, NY, USA) at 5μg/ml and 10μg/ml, respectively, in 0.1M NaHCO3 buffer, pH 9.6 
(50μl). The plate was incubated overnight at 4oC. The plate was then washed three times 
with wash buffer solution (0.1% Tween 20 in PBS), and blocked with 2% BSA, 0.1% 
Tween 20 in PBS at 37 oC for 1 hr. After removal of the blocking solution, 50μl of the 
sera (1 in 50 dilutions for testing of EDIII and 1 in 500 dilutions for testing of L. lactis) 
were added. The plate was incubated at 37 oC for 1 hr. After three washings, the plate was 
treated with 50μl of anti-mouse IgG (H+L) HRP conjugate (Bio-rad, USA) (1:5000 
dilutions) and incubated at 37 oC for 1 hr. The plate was washed and a yellow colour was 
generated after the addition of 50 μl of SigmaFast™ O-phenylenediamine 
dihydrochloride substrate (stock solution; 1 tablet per 20ml of dH2O, Sigma-Aldrich, Inc. 
St Louis, Missouri, USA), followed by incubation in the dark at room temperature for 1 
hr. The reaction was stopped using 75 μl of 1M H2SO4 and measured using ELISA plate 
reader (Bio-rad model 680 microplate reader, USA) with the absorbance at OD490 were 
recorded using the microplate manager 5.2 software (Bio-rad, USA).     
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3.6.2. Persistence studies 
3.6.2.1 Mouse strains  
Mice were purchased from Biological Resource Centre, Biopolis, Singapore. Two 
strains of mice were used for both lung (nasal route) and intestine (oral route) 
colonization studies, namely BALB/c and C57BL/6. Four 5-6 week old female mice were 
used for each time point.  
 
3.6.2.2 L. lactis persistence in the lungs 
108CFU of bacterial suspension were intranasally inoculated into each mouse as 
described in section 3.6.1.2. At 3 hr, 24 hr, 48 hr and 72 hr post-inoculation, 4 mice per 
group were sacrificed, the lungs were harvested in 5ml sterile PBS and homogenized (Fig 
3.2A). Appropriate dilutions of the suspension were then plated on GM17 agar containing 
10 µg/ml erythromycin.  
3.6.2.3 L.lactis persistence in the intestines  
1010CFU of recombinant L. lactis were orally administered to the animals as 
described in section 3.6.1.3. The fecal samples were collected at 3 hr, 24 hr, 48 hr and  
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72 hr post-gavage, and pooled for each group (Fig 3.2B). These pellets were weighted 
and re-suspended in sterile PBS at a final concentration of 100mg/ml. After extensive  
homogenization, the suspension was allowed to settle for two hours. Appropriate 
dilutions of the suspensions were plated onto GM17 agar with 10 µg/ml of erythromycin. 
 
3.7 Statistical analysis 
 Data was analyzed using Student's t-test for measurement of antibodies in the 
serum of the mice. Results were considered statistically significant when P < 0.05 and 
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Chapter 4: Results 
 
4.1 Persistence studies of L. lactis in BALB/c and C57BL/6 mouse  strains 
 
 In order to determine the ability of the EDIII-producing L. lactis strain 
(LLWE-EDIII) to persist in the lung and into the gastro-intestinal tract, persistence 
studies were carried out in both BALB/c and C57BL/6 mouse strains after nasal and 
oral single administration, respectively.  
 For the lung persistence studies, the mice received 108 CFU via the nasal route 
and, at different time points (3, 24, 48 and 72 hours), the lungs were collected, 
homogenized and plated as described in the Materials & Methods section. The results 
obtained showed that the bacteria were totally cleared from BALB/c mice 48 hours 
post-administration (Fig 4.1 A) whereas a significant amount (2 logs) of bacteria were 
still detected in C57BL/6 mice at the same time (Fig. 4.1B). These results indicate 
that the L. lactis LLWE-EDIII strain persists longer in the lungs of C57BL/6 than in 
BALB/c mice upon nasal administration. 
 The persistence ability of L. lactis in the gastro-intestinal tract was assessed 
by counting bacteria recovered in the feces of the animals. Feces homogenates were 
plated onto medium containing erythromycin in order to select for the EDIII-
producing L. lactis bacteria (LLWE-EDIII) from the complex intestinal microbial 
flora. However, before oral administration of the LLWE-EDIII bacteria, a basal level 
(approximately 103 CFU/ml) of erythromycin-resistant bacteria was observed in both 




























Figure 4.1:  Lung persistence in BALB/c (A) and C57BL/6 (B) mice after 
nasal administration of L. lactis recombinant strain LLWE-EDIII.  
108 CFU were nasally administered to the mice and at the indicated time points, the 
mice were sacrificed, the lungs were collected, homogenized and appropriate 
dilutions were plated on erythromycin containing GM17 agar. Four mice per group 
and per time point were individually assessed. The standard deviation is calculated 




Figure 4.2: Intestine persistence in BALB/c (A) and C57BL/6 (B) mice after 
oral administration of L. lactis recombinant strain LLWE-EDIII. 
Before administration of the L. lactis bacteria, the presence of erythromycin bacteria 
in the gastrointestinal tract of the animals was assessed (white bars). Then, 1010 CFU 
were given orally to the mice (black bars) and at the indicated time points, the pooled 
feces were collected, homogenized and appropriate dilutions were plated onto 
erythromycin containing GM17 agar plates. Groups of four mice were assessed for 
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1010 CFU were orally administered to each mouse and at 3, 24, 48 and 72 hours, the 
feces were collected, homogenized and plated. 
 The results show that the bacteria are progressively cleared from the gastro-
intestinal tract, coming back to the basal level of erythromycin-resistant bacteria 
within 72 hours (Fig 4.2A and Fig 4.2B). No significant difference was observed 
between BALB/c and C57BL/6 mice in the ability of L. lactis to persist in the gastro-
intestinal tract. 
 
4.2 Sero-conversion of inoculated mice against L. lactis 
 The systemic anti-lactococcal total IgG response has been studied in three 
different groups of mice: naïve mice, mice which have received pMG36E backbone 
plasmid-transformed L. lactis strain (LLWE), and mice which have received EDIII-
producing L. lactis strain (LLWE-EDIII). BALB/c and C57BL/6 mouse strains were 
studied after oral or nasal administration. The immunization schedules and bleeding 
time points are schemed in Figure 4.3.   
 Naive BALB/c mice showed a stable IgG against L. lactis from the ELISA 
reading of antibody at OD490nm throughout the experiment (Fig 4.4A and Fig 4.5A), 
whereas naïve C57BL/6 mice were found to   display a marked increase of the 
OD490nm reading at day 77 and 91 (Fig. 4.4B and Fig. 4.5B). 
 BALB/c mice nasally inoculated with LLWE strain showed a significant 
increase of OD490nm for bleeding at day 77 and 91 (Fig. 4.4A). For the BALB/c mice 
nasally inoculated with LLWE-EDIII strain, an overall constant OD490nm reading was 
observed with values not significantly different from the values measured in naïve 
mice (Fig. 4.4A). 





prime boost 1 boost 2 bleedingbleedingbleeding boost 3 bleeding boost 4 bleeding
Day 0 14 28 70 8442 56 77 9169
Nasal immunization schedule and bleeding
prime boost 1 boost 2 bleedingbleedingbleeding boost 3 bleeding boost 4 bleeding
Day 0,1,2 14,15,16 28,29,30 70,71,72 84,85,8642 56 77 9169
Oral immunization schedule and bleeding
Figure 4.3: Immunization schedules and bleeding after nasal (A) or oral (B) 
administration of L. lactis strains (either LLWE or LLWE-EDIII).  
The arrows indicate the days of manipulation of mice for either inoculation or bleeding. The naïve group of mice 
consist of 4 mice per group while the LLWE and LLWE-EDIII inoculated mice consist of 6 mice per group. On 






































































































































Figure 4.4 Detection of anti-L. lactis IgG antibodies in the serum of BALB/c (A) and 
C57BL/6 (B) mice after nasal administration of L. lactis strains.  
The serum of six mice per group was assessed individually by ELISA. Results are expressed as the mean and 
standard deviation. Plates were coated with a total L. lactis lysate. Columns with dots represent naïve mice. 
Stripped columns represent LLWE inoculated-mice and white columns represent LLWE-EDIII inoculated-mice. 
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The nasally inoculated C57BL/6 mice showed instead a marked increase of the anti-
lactococcal IgG response after the third and forth boosts (bleeding at day 77 and 91), 
and this trend was observed for all three groups (naïve, LLWE and LLWE-EDIII) 
(Fig 4.4B).   
 BALB/c mice orally inoculated with LLWE and LLWE-EDIII strains showed 
a marked increase of the anti-lactococcal IgG response after the third and fourth 
boosts (bleeding at days 77 and 91) (Fig 4.5A). For C57BL/6 orally inoculated with 
LLWE or LLWE-EDIII, the anti-lactococcal antibody response appears constant (if 
we exclude day 56 time point) throughout the experiment (Fig 4.5B). 
 In summary, BALB/c and C57BL/6 mice did not produce any significant anti-
lactococcal antibody response before day 77. The third and fourth boosts clearly 
triggered the systemic production of anti-lactococcal antibodies in BALB/c mice 
(nasal and oral route of administration), whereas C57BL/6 did not show any 
significant differences compared to the naïve group.  
In conclusion, our observations suggest that C57BL/6 mice appear more immune-
tolerant to L. lactis bacteria compared to BALB/c mice. 
  
4.3 Sero-conversion of inoculated mice against dengue NGC EDIII 
 
 We first compared the performance of an in-house EDIII-coated ELISA to the 






















































































































 Figure 4.5 Detection of anti-L. lactis IgG antibodies in the serum of BALB/c (A) and 
C57BL/6 (B) mice after oral administration of L. lactis strains.  
The serum of six mice per group was assessed individually by ELISA. Results are expressed as the mean and 
standard deviation. Plates were coated with a total L. lactis lysate. Columns with dots represent naïve mice. 
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(PanBio, Australia) where the four Dengue serotypes total viruses have been coated 
onto each well. The in-house EDIII-coated ELISA was found to be more sensitive 
and accurate for the detection of anti-EDIII antibodies (data not shown). All the 
readings were standardized using envelope-specific monoclonal antibody 3H5 
(#8702, Chemicon international, USA) (OD490nm reading of 1.019) as positive control. 
For both strains of mice, an additional group was intraperitoneally inoculated with 
heat-inactivated dengue serotype 2 (NGC strain) and was considered as the gold 
standard against which the production of anti-EDIII antibody production has been 
compared.  
 The serum of the naïve BALB/c mice gave an absorbance at OD490nm 
comprised between 0.147 and 0.619 throughout the experiment (Fig 4.6A and Fig. 
4.8A). Therefore, we considered that OD490nm 0.619 represents the threshold value 
above which serum samples are positive. For the BALB/c mice nasally inoculated 
with LLWE strain, 5 mice at day 69 and 3 mice at day 77 showed an absorbance 
reading at OD490nm above the threshold (Fig. 4.6B).  
 For the LLWE-EDIII inoculated-BALB/c mice, mice M1 and M3 were found 
with a positive absorbance reading at OD490nm (above the threshold) at day 42, 56 and 
69 (Fig. 4.6C). And were observed to be statistically significant for their sera readings 
at day 56 ( P < 0.05).  However, The OD490nm values were significantly lower than 
that obtained for the NGC-injected mouse group (0.889). The naïve C57BL/6 mice 
gave an absorbance at OD490nm below 0.48 throughout the experiment, with the 
exception of mice 4 at day 91 (Fig 4.7A).  
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Figure 4.6: Detection of anti-EDIII IgG antibodies in the serum of BALB/c 
mice after nasal administration of L. lactis strains.  
The serum of six mice per group was assessed individually by ELISA. Plates were 
coated with a purified EDIII. (A) naïve mice, (B) LLWE inoculated-mice, (C) 
LLWE-EDIII inoculated-mice. Solid arrows (↑) on the X axis denote priming and 
boostings. Horizontal dash line denotes cut-off value for serum positivity. The sera of 
the NGC dengue virus-injected mice were pooled before ELISA tested.  Legend: * 
monoclonal antibodies (3H5)  
 mice intraperitoneally inoculated with heat-inactivated dengue (NGC); ◊ mouse 1; ■   
mouse 2; ▲mouse 3; x mouse 4;  □ mouse 5; + mouse 6.     
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Figure 4.7: Detection of anti-EDIII IgG antibodies in the serum of C57BL/6 
mice after nasal administration of L. lactis strains.  
The serum of six mice per group was assessed individually by ELISA. Plates were 
coated with a purified EDIII. (A) naïve mice, (B) mice inoculated with LLWE strain 
and (C) mice inoculated with LLWE-EDIII strain. Solid arrows (↑) on the X axis 
denote priming and boostings. Horizontal dash line denotes cut-off value for serum 
positivity. Symbol legend: see Fig. 4.6    
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 An OD490nm of 0.48 was therefore considered as the threshold. For C57BL/6 
mice nasally inoculated with LLWE strain, the absorbance reading remains below or 
similar to the threshold value up to day 69. However after the third boost (day 77), 
five mice were found transiently with OD490nm readings clearly above the threshold, 
but wean to readings below the threshold on day 91, with the exception of mouse M3 
(Fig 4.7B).  Mouse M5 died after bleeding at day 77.  
 For the LLWE-EDIII nasally inoculated-C57BL/6 mice, 3 mice (M1, M4 and 
M5) out of 6 were found for all the bleeding time points with OD490nm values above or 
similar to the value obtained for the NGC-injected group (0.889) (Fig. 4.7C). And 
were statistically significant (P < 0.05) for sera of days 42 and 56. The readings for 
sera of day 69 were highly significant (P < 0.01) for these mice. Mouse M2 was 
found with positive OD490nm value after the fourth boost only (day 91) but was not 
statistically significant (P > 0.05). Mice M3 and M4 died after bleeding at day 77. 
 In conclusion, the C57BL/6 mice nasally inoculated with LLWE-EDIII clearly 
gave higher absorbance readings compared with BALB/c mice nasally inoculated 
with the same L. lactis recombinant strain. These results indicate that C57BL/6 mice 
produced a greater systemic anti-EDIII antibody response than BALB/c mice when 
nasally administered with the EDIII-producing L. lactis strain.  
 For the BALB/c orally inoculated with LLWE strain, the readings were found 
below the threshold with the exception of mouse M5 after day 69 (Fig 4.8B). For 
BALB/c orally inoculated with LLWE-EDIII, 5 mice (M1, M2, M3, M4 and M6) out 
of 6 displayed absorbance readings above the threshold on day 69 (Fig. 4.8C) and 
were statistically significant ( P < 0.05). 
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Figure 4.8: Detection of anti-EDIII IgG antibodies in the serum of BALB/c 
mice after oral administration of L. lactis strains.  
The serum of six mice per group was assessed individually by ELISA. Plates were 
coated with a purified EDIII. (A) naïve mice, (B) mice inoculated with LLWE strain 
and (C) mice inoculated with LLWE-EDIII strain. Solid arrows (↑) on the X axis 
denote priming and boostings. Horizontal dash line denotes cut-off value for serum 
positivity.  
Symbol legend: see Fig. 4.6. 
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Figure 4.9: Detection of anti-EDIII IgG antibodies in the serum of C57BL/6 
mice after oral administration of L. lactis strains.  
The serum of six mice per group was assessed individually by ELISA. Plates were coated 
with a purified EDIII. (A) naïve mice, (B) mice inoculated with LLWE strain and (C) 
mice inoculated with LLWE-EDIII strain. Solid arrows (↑) on the X axis denote 
priming and boostings. Horizontal dash line denotes cut-off value for serum 
positivity.  
Symbol legend: see Fig. 4.6. 
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However, only mouse M4 had an OD490nm value above the value obtained for the 
NGC-injected group (0.889). This antibody response then decreased after the 3rd 
boost, and only three mice left (M4, M5 and M6) were found with OD490nm values 
above the threshold at day 77 (Fig 4.8C). After the fourth boost, none of the mice 
showed positive OD490nm. 
 The absorbance readings obtained for the C57BL/6 mice orally inoculated 
with LLWE strain, were not found significantly higher than the threshold (P > 0.05) 
(Fig 4.9B). However, the readings were stable throughout the experiment and did not 
fluctuate beyond the range of 0.6-0.9 except for mouse M1 on day 77. For C57BL/6 
mice orally inoculated with LLWE-EDIII strain, all the six mice had reading values 
above the threshold, but only two of them (mice M2 and M3 at day 42, 56 and 69, 
and mice M3 and M4 at day 77) showed values above the value obtained for the 
NGC-injected group (Fig 4.9C). These readings were found highly significant (P < 
0.01) when compared to the naïve and LLWE groups. Mouse M6 died after second 
boost and mice M3 and M5 died after bleeding at day 77.  
 In conclusion, the C57BL/6 mice orally inoculated with LLWE-EDIII gave 
higher readings when compared with BALB/c mice. The C57BL/6 group showed 
more mice than the BALB/c group having OD490nm values higher than the value 
obtained for the NGC-injected group (3 C57BL/6 mice compared to 1 BALB/c 
mouse).   
 
 Altogether, our data indicate that C57BL/6 mice nasally inoculated with 
LLWE-EDIII strain produced the highest and the most sustained anti-EDIII antibody 
response, compared to BALB/c mice and compared to the oral route.  




4.4 Detection of neutralizing antibodies in the recombinant L. lactis-inoculated mice 
 
 To further study the protective potential of the EDIII-producing L. lactis 
strain, the presence of neutralizing antibodies in the serum of the inoculated animals 
was determined by plaque reduction neutralizing test (PRNT). The envelope-specific 
monoclonal antibody 3H5 (#8702, Chemicon international, USA) was used as 
positive control, since it has been shown to neutralize dengue viral challenge and 
since neutralizing epitopes were found to be located within domain III (EDIII) (Crill 
et al., 2001; Beasley et al., 2002; Hermmida et al., 2006). The serum from the NGC-
injected group was also used as a positive control at a sera dilution of 1:10.  The sera 
of naïve and LLWE-inoculated mice were pooled and used at a dilution of 1:10. For 
the LLWE-EDIII inoculated-mice, the individual sera for which high anti-EDIII IgG 
titers were obtained were selected and assayed in PRNT. As such, the serum from 
BALB/c mouse M3 of orally inoculated with LLWE-EDIII was tested (bleeding at 
day 69, see Fig.4.8C). And the serum from C57BL/6 mice M2 and M3 orally 
inoculated with LLWE-EDIII were also tested (bleeding at day 69, see Fig 4.9C).  
 The results showed that the pooled sera from the naïve and LLWE inoculated-
mice have no neutralizing activity against the dengue virus (NGC strain) (Fig 4.10A 
and B).  Instead, the serum from BALB/c M3 mouse was found to efficiently 
neutralize the dengue virus (Fig. 4.10A). The percentage of inhibition obtained for the 
sera diluted 1/10 indicated that the neutralizing potential of the M3 serum might be 
lower than the serum from the NGC-injected group (43.4% and 62.5% inhibition, 
respectively). However, similar neutralizing efficiencies were found at dilution 1/20 
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(about 25% inhibition). This observation suggests that the neutralizing ability of the 
serum from the orally inoculated BALB/c M3 mouse is comparable to the 
neutralizing ability of the serum from the NGC-immunized mice. 
 The serum from the orally inoculated C57BL/6 M2 mouse showed a lower 
ability to neutralize dengue (NGC) compared to the serum from the NGC-immunized 
mice (Fig. 4.10B). However, at dilution 1/40, both sera gave similar percentage of 
inhibition (around 10%). The serum from M3 mouse was found more efficient to 
neutralize the virus than the serum from the NGC-immunized group, as it gave 
consistent higher percentages of inhibition at all dilutions tested (Fig. 4.10B).  
 In conclusion, the sera from orally LLWE-EDIII inoculated-mice (BALB/c 
and C57BL/6) were able to neutralize the NGC dengue virus in an in vitro plaque 
reduction neutralizing test (PRNT), with an efficacy comparable to or even higher 
than the one obtained with the serum from mice immunized with the whole NGC 
virus. 
 The serum from mice nasally inoculated with LLWE-EDIII strain is being 
























































Figure 4.10: PRNT of orally inoculated BALB/c (A) and C57BL/6 (B) with  
                      LLWE-EDIII 
Legend:▲monoclonal antibodies (3H5);     mice intraperitoneally inoculated with 
heat-inactivated dengue (NGC); ■ pooled naïve mice; x pooled mice inoculated with 
LLWE mice; individual mice inoculated with LLWE-EDIII , (panel A)□ mouse 4 and 










































































Chapter 5:  Discussion 
 
 Mucosal vaccines, which are administered by oral or intranasal route, are more 
convenient than the usual parenteral vaccines due to their ease of administration and low 
cost. Both are priorities for developing countries plagued by infectious diseases when 
considering vaccination for public health policy. Moreover, mucosal vaccines are able to 
elicit serum-IgG and mucosal-IgA antibodies to neutralize toxins and viruses and induce 
cytotoxic T lymphocytes (CTL) activities (Levine et al., 1998).  
 In this context, we have embarked on the study of the use of Lactococcus lactis as 
a possible vaccine vector targeting dengue virus. This is a further study from previous 
work by Lin, W. (2006) who constructed a recombinant L. lactis strain producing in its 
cytoplasm the E domain III (EDIII) antigen from DEN2 virus, Singapore strain. L. lactis 
is a noninvasive, nonpathogenic, gram-positive bacterium which has a long history of 
widespread use in the food industry for the production of fermented milk products, thus it 
has a generally-regarded as safe (GRAS) status (Adam et al., 1995). Its GRAS status 
coupled to its inability to colonize the digestive and the respiratory tracts of both humans 
and mice, except gnotobiotic mice, make L. lactis a safe and attractive vaccine delivery 
vehicle for human use (Gruzza et al., 1994; Klijin et al., 1995; Vesa et al., 2000).  
 This study aims to study the immunization efficacy of the EDIII-producing L. 
lactis strain (LLWE-EDIII), via measuring the systemic anti-EDIII antibody response 
generated in two different mouse strains, BALB/c and C57BL/6, after nasal or oral 
administration. 
 Previous studies have established a correlation between persistence efficiency of 
lactic acid bacteria in the host and their protective potential (Grangette et al., 2002; 
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Oliveira et al., 2006). The persistence of the LLWE-EDIII bacteria in the respiratory and 
gastro-intestinal tracts was determined in both BALB/c and C57BL/6 mice after nasal 
and oral administration, respectively. The recombinant bacteria administered via the nasal 
or oral route were progressively cleared from the respiratory or gastro-intestinal tract of 
the animals within 48 or 72 hours. Bacteria were found to persist longer in the respiratory 
tract of C57BL/6 mice compared to the BALB/c mice, as a significant amount of bacteria 
(approx. 2.5 log) were still recovered from the lungs of C57BL/6 mice after 48 hours 
whereas the lungs of BALB/c mice were totally sterile at the same time point. No 
difference in the persistence of LLWE-EDIII bacteria was observed between both mouse 
strains after oral inoculation. Our observations are in agreement with previous studies 
which reported varying abilities to recover inoculated L. lactis in different mouse strains 
and via different routes of inoculation (Norton et la., 1994; Klijin et al., 1995; Drouault et 
al., 1999; Grangette et al., 2002; Oliveira et al., 2006). In these studies, the persistence of 
L. lactis bacteria ranged from none to three days post-inoculation. This study was carried 
out to study whether the cytoplasmic production of the EDIII antigen in L. lactis affects 
the persistence of the bacteria in the respiratory tract of the animals. A correlation 
between persistence of L. lactis and antibody raised against it has indeed been 
demonstrated (Norton et al., 1984).  
Moreover, we have observed that naïve BALB/c and C57BL/6 mice displayed a 
basal level (103 CFU/ml) of erythromycin resistant bacteria. This basal level of inherent 
erythromycin-resistant bacteria has also been observed by Grangette et al. (2002) 
although it only appeared 4 days after administration of recombinant L. lactis strain 
producing tetanus toxin fragment C.   
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 LAB have been described to induce tolerance which is one of the advantage to use 
them as vaccine delivery vehicle, as repeated administrations will not lead to a faster 
clearance of the recombinant bacteria (Wells et al., 1995; see survey of literature section 
2.5.2). The systemic anti-lactococcal antibody response was determined in BALB/c and 
C57BL/6 naïve mice and in mice nasally or orally inoculated with LLWE or LLWE-
EDIII strains. 
 The naïve C57BL/6 mice displayed a marked increase of the OD490nm reading at 
day 77 and 91. Our observation is in agreement with a previous study describing the 
increase of enteric anti-L. lactis IgA antibodies in naïve C57BL/6 mice as they grew 
older (Norton et al., 1994). The authors postulated that environmentally encountered 
cross-reacting bacteria might be responsible for the positive detection of anti-lactococcal 
antibodies. We observed instead a basal and constant OD490nm reading for the naïve 
BALB/c mice, suggesting that BALB/c mice are more tolerant to environmental bacteria 
than C57BL/6 mice. 
 The C57BL/6 mice nasally inoculated with LLWE or LLWE-EDIII bacteria 
showed a comparable profile and similar OD490nm values to that observed for the naïve 
C57BL/6 mice. The C57BL/6 mice orally inoculated produced an overall constant anti-
lactococcal antibody response throughout the experiment, with OD490nm values similar to 
the values obtained for naïve C57BL/6 mice at day77 and 91. These results suggest that 
the repeated nasal or oral administrations of L. lactis bacteria do not trigger the 
production of anti-lactococcal antibodies in the serum of C57BL/6 mice.  
 Instead, the BALB/c mice orally inoculated with LLWE or LLWE-EDIII showed 
a marked increase of the anti-lactococcal antibody response after the 3rd and 4th boosts. A 
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previous study has also described that the systemic anti-lactococcal IgG antibody 
response was enhanced in BALB/c mice after oral inoculation of L. lactis (Norton et al., 
1984). Similarly, BALB/c mice nasally inoculated with LLWE strain showed a marked 
increase of the anti-lactococcal antibody response after the 3rd and 4th boosts.  
 Altogether, these data indicate that C57BL/6 mice are less prone than BALB/c 
mice to develop a systemic anti-lactococcal antibody response, and therefore appear more 
tolerant to repeated nasal or oral administrations of L. lactis bacteria than the BALB/c 
mice.  
 The specific anti-EDIII antibody response was determined in the serum of 
BALB/c and C57BL/6 mice nasally or orally inoculated with the recombinant L. lactis 
strain LLWE-EDIII. An in-house ELISA assay was developed in which purified His-
tagged EDIII was used as coating antigen. The pooled sera of C57BL/6 or BALB/c mice 
intraperitoneally injected with heat-inactivated dengue virus (NGC strain) provided a 
gold standard reference against which the OD490nm readings were compared. 
Overall, our results showed clearly that i) C57BL/6 mice inoculated with LLWE-
EDIII bacteria produced a higher systemic anti-EDIII IgG response than the BALB/c 
counterparts, and ii) the nasal route triggered a stronger and more sustained systemic 
response than the oral route in those C57BL/6 mice. Three out of six C57BL/6 mice 
nasally inoculated with LLWE-EDIII bacteria were found indeed with antibody titers 
significantly higher than the titer obtained for the NGC-injected group. Such titers were 
observed already after the second boost (bleeding at day 42) and were sustained up to at 
least day 77 for the three mice. Instead, only two C57BL/6 mice orally inoculated with 
LLWE-EDIII bacteria showed antibody titers above the titer obtained for the NGC-
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injected group, and such a response decreased markedly after the third boost (bleeding at 
day 77), coming back to the threshold value at day 91. The observation that the nasal 
administration of recombinant L. lactis triggered a better systemic antibody response than 
the oral route is in opposition to previous reports in which the oral administration of 
recombinant L. lactis bacteria was found better than the nasal administration (Pei et al., 
2005; Xin et al., 2003). However, these studies were all carried out in BALB/c mice and 
true enough, if we compare the anti-EDIII antibody response triggered in BALB/c mice 
nasally or orally inoculated with LLWE-EDIII bacteria, it appears that indeed the oral 
route clearly triggered higher titers than the nasal route (Fig 4.6 and Fig 4.8). 
 In the nasally inoculated C57BL/6 mice, only three mice out of six were found to 
produce significant anti-EDIII IgG antibodies in their serum. Similarly, Kim et al. (2005) 
described that only two out of five C57BL/6 mice orally inoculated with a recombinant L. 
lactis MG1363 strain expressing an H. pylori vaccine candidate on the pMG36 plasmid, 
generated H. pylori antigen-specific antibodies. Perez and co-workers (2005) also 
reported that only two out of five mice (BALB/c) inoculated with rotavirus antigen 
secreting-L. lactis elicited a specific-antibody response. Another study using an HPV 
antigen-producing L. lactis strain reported that only 35% of the mice (C57BL/6) were 
protected from tumour formation (Bermudez-Humaran et al., 2005). It  appears therefore 
that the nasal or oral administration of recombinant L. lactis strains generally triggers a 
significant specific (protective) immune response in only 50% or less of the immunized 
animals. It is not clear what technical and/or physiological parameter(s) might be critical 
during mucosal administration. The lack of full understanding of mucosal immunity 
might contribute to the inability to ensure that the majority of the mice respond to 
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inoculation. However, the expression of heterologous antigens with cytokines in L. lactis 
has been shown to enhance the immunity against such antigens (Bermudez-Humaran et 
al., 2004; Grangette et al., 2002; Steidler et al., 1998, 2000) The use of L. lactis 
expressing IL-10 has also been approved by Dutch authorities for phase I clinical trials 
for treatment of inflammatory bowel diseases ( Steidler et al., 2003). 
Overall, we have observed a decrease in the anti-EDIII antibody titer after the 
third boost for most of the mice from both strains and regardless of the route of 
inoculation. This phenomenon might be due to the induction of immune tolerance to 
EDIII antigen after the third boost. Antigen tolerance has also been observed in mice 
inoculated with recombinant L. lactis bacteria expressing the urease subunit B of H. 
pylori (Lee et al., 2001), or producing the MSP-119 antigen from Plasmodium yoelii 
(Zhang et al., 2005). The induction of antigen tolerance could depend on several factors 
including the dose, frequency and interval of administration of the recombinant bacteria 
(Weiner, 1994). Therefore, the third and forth boosts might be non-beneficial or even 
detrimental to the production of a strong and sustained specific antibody response. 
The importance of neutralizing antibodies to protect from dengue has been 
demonstrated by the protection of mice passively transferred with monoclonal antibodies 
(Kaufman et al., 1987; 1989). Moreover, due to a lack of a reliable animal model for 
dengue, neutralizing antibody titers and plaque reduction neutralizing test (PRNT) are 
widely used as surrogate markers of protective immunity (Putnak et al., 1991; Delenda et 
al., 1994). The sera of the mice for which a significant anti-EDIII antibody titer was 
measured, were assayed in a PRNT. 
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Our results showed that the serum from mice orally inoculated with LLWE-EDIII 
strain was able to neutralize NGC virus at least as efficiently as the serum from mice 
immunized with the whole NGC virus. The serum from mice immunized with NGC virus 
does contain antibodies against the whole virus, whereas the serum from LLWE-EDIII 
inoculated-mice does contain EDIII-antibodies only. Moreover, the sera from the orally 
inoculated-mice tested in PRNT showed anti-EDIII titers significantly higher than the 
titer obtained for the NGC-immunized mice. This observation indicates that when EDIII 
is the only antigen used for vaccination, higher anti-EDIII antibody titers might be 
necessary in order to achieve a neutralizing activity comparable to the one obtained with 
a whole virus-immunization. Our data therefore suggest that EDIII antigen does contain 
important neutralizing epitopes, however some additional neutralizing epitopes are 
present in the virus as well. Alternatively, another hypothesis can be proposed: The EDIII 
antigen produced in the LLWE-EDIII strain has been cloned from the Dengue 2 SING/99 
strain, whereas Dengue 2 NGC strain has been used to carry out the PRNT. A recent 
study has shown that the antibodies raised against SING/99 strain are able to neutralize 
NGC strain despite amino acid variation of 3% between the two homotypic strains (Lim 
et al., 2006). Within the EDIII region, the two strains differ in 3 amino acids (Lim et al., 
2006). Thus, the ability of anti-EDIII (SING/99) antibodies to neutralize NGC virus 
might be lower than anti-EDIII(NGC) antibodies, which might require a higher antibody 
titer to achieve similar  protection levels.   




Chapter 6: Conclusion and future directions 
 
This study was carried out in order to determine the suitability of L. lactis for 
dengue antigens vaccine delivery. Recombinant L. lactis bacteria producing 
intracellularly EDIII antigen from DEN2 Singapore strain, were administered to 
BALB/c or C57BL/6 mice via the oral or the nasal route. The systemic specific anti-
EDIII IgG responses were compared. Our data indicate that the nasal administration 
of EDIII-producing L. lactis bacteria triggers a strong and sustained antibody 
response against EDIII antigen in the serum of C57BL/6 mice. Moreover, we have 
shown that the sera from orally inoculated mice for which high anti-EDIII titers were 
measured, are able to efficiently neutralize Dengue NGC strain in an in vitro 
neutralization assay. The sera from the nasally inoculated mice are being currently 
tested in the laboratory. 
Despite the lack of a proper animal model, there is still a need to prove the 
protective ability of our recombinant L. lactis producing EDIII antigen against viral 
challenge in vivo. The various current mice models (refer to survey of literature 2.6.1) 
can be taken as reference for our future studies with the various means of dengue 
virus infection and proof of protection in various strains of mice could also be taken 
into consideration. 
It would also be of interest to study the T cell response in the immunized 
animals by monitoring the magnitude of cell proliferation and production of cytokines 
such as IFN-γ (a Th1 cytokine) and IL-4 (a Th2 cytokine) upon activation in vitro by 
purified EDIII antigen of the splenocytes isolated from immunized mice. The 
importance of T cell response for dengue infection has been observed by Khanam et 




al. (2006) and An et al. (2005) where higher Th1 response was found to be involved 
in the virus clearance. Moreover, T cells obtained from PBMC of dengue infected 
patients were able to recognize E proteins (Rothman et al., 1996). The ability of 
recombinant L. lactis in eliciting a T cell response was observed by Pei et al. (2005) 
and Ramasamy et al. (2006). The involvement of both Th1 and Th2 CD4+ cell 
activity was also observed in C57BL/6 inoculated with recombinant L. lactis 
expressing tetanus toxin fragment C (Norton et al., 1997). 
Due to the distinct four serotypes of dengue, a tetravalent vaccine is required. 
The construction of recombinant L. lactis strains expressing each EDIII antigen of 
each serotype may be an interesting approach. However, the administration of a 
tetravalent vaccine at a single site of inoculation might result in viral interference or 
immuno-dominance against a single serotype. The inoculation at different sites (oral, 
nasal…) which drains to physiologically distinct lymph nodes might be of particular 
interest. Targeting of distinct lymph nodes has shown promise in Sendai virus and 
cancer experiments in mice (Cole et al., 1997; Makki et al., 2002).  
 In order to lower the anti-carrier response so as to increase the number of 
immunizations, L. lactis bacteria can be acid pre-treated to remove surface 
components, leaving a non-living particle that is termed Gram-positive enhancer 
matrix (GEM) (Steen et al., 2003; Bosma et al., 2006). GEM has been shown to 
trigger a lower anti-carrier response compared to live L. lactis, but still efficiently 
elicit antibodies against the heterologous antigen they produce (Ramasamy et al., 
2006). Recombinant L. lactis bacteria secreting a H. pylori vaccine candidate has 
been shown to trigger a higher systemic antigen-specific antibody response than 




recombinant L. lactis bacteria which produced the vaccine antigen intracellularly 
(Nouaille et al., 2003). Cell anchored HPV antigen in recombinant L. lactis was also 
shown to elicit a higher immune response than L. lactis intracellularly expressing the 
same antigen (Bermudez-Humaran et al., 2005). Thus, the construction of 
recombinant L. lactis strains secreting or surface-expressing EDIII antigen might be 
undertaken in order to further improve the specific immune response in C57BL6 mice 
upon nasal administration. 
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Appendix 1: Reagents for BHK cells culture  
 
 
1.1 Growth and Maintenance Media 
 
1.1.1 Fetal Calf Serum (FCS) 
 
FCS (Gibco BRL, USA) was inactivated by heating at 56 oC for 30 min, aliquoted 
and stored at -200C. 
 




NaCl                                                 80.0g 
 
KCl                                                     2.0g 
 
KH2PO4                                              2.0g 
 
Na2.HPO4                                                               11.5g 
 
To prepare the 10x PBS stock solution, the specified constituents were added to 
900ml of nanopure water and pH adjusted to 7.4. The stock solution was top up to 
1 L and then autoclaved at 121 oC for 15 min. The stock solution was then stored 
at room temperature.  
To prepare the working (1x) PBS, 10x PBS stock solution was diluted 1:10 with 
nanopure water. The solution was then autoclaved at 121oC for 15min and 
subsequently stored at 4 oC. 
 
1.1.3 Trypsin/Versene Solution 
 
The 10X trypsin/versene solution (JRH biosciences, Kansas, USA) was diluted to 
1 X trypsin/versene solution using 1 x PBS solution as diluent.  
 
1.1.4 RPMI medium 1640 
 
RPMI medium 1640 with L-glutamine 1 packet 
 
HEPES buffer solution (1M)                          20ml 
 
NaHCO3                                                                                       15ml 
 
FCS                                                                 10% final concentration for growth; 
2% final concentration for 
maintenance in plaque assays. 





1 packet of RPMI medium 1640 powder was dissolved in 500ml of nanopure 
water. Two ml of NaHCO3 (Sigma-Aldrich Inc. was then added and the pH 
adjusted to 7.2. The final volume was then increased to 900ml and sterilization 
carried out by filtration through a 0.2μm membrane.  
The media was then stored in aliquots at 4 oC. FCS was added as required prior to 
use. 
 
To make double strength RPMI medium for use in plaque assay, the same 
constituents were dissolved in a final volume of 480ml of nanopure water instead 
of 900ml. FCS was added to a final concentration of 2%. 
 
 
1.2 Reagents for Plaque Assay 
 
1.2.1 2% Carboxymethylcellulose (CMC) 
 
To make 100ml of 2% CMC, 2.0g of carboxymethylcellulose (Aquacide II, 
Calbiochem) was resuspended in 100ml of nanopure water. The suspension was 
then autoclaved for 15 minutes at 1210C and then kept at 40C. 
 
1.2.2 Medium used for plaque assay 
 
Two hundred ml of plaque assay medium were made by combining 100ml of 2% 
CMC with 299ml of double strength RPMI 
 
1.2.3 Solution for staining plaque assay plates 
 
Crystal violet (Sigma,USA)          5g (1% final) 
37% formaldehyde (Merck)          270ml (20% final) 
PBS (Appendix 1.1.2)                   230ml 
 
 
 
 
